KALA BIO, Inc. announced that it has entered into a Securities Purchase Agreement with certain institutional investors 9,393 Series H convertible non-redeemable preferred shares at a price of $585 per share for the gross proceeds of $5,494,905 and 1,197,314 common shares at a price of $5.85 per share for the gross proceeds of $7,004,286.9, for total gross proceeds of $12,499,191.9 on June 26, 2024. The transaction will include participation from returning investors 667, L.P. for 61,602 common shares and 226 preferred shares, Baker Bros. Advisors LP managed by Baker Brothers Life Sciences, L.P. for 563,120 common shares and 2,073 preferred shares and new investors ADAR1 Partners, LP managed by ADAR1 Capital Management, LLC for 112,170 common shares and 2,597 preferred shares and Sr One Capital Fund Ii Aggregator, Lp managed by SR One Capital Management, LP.

for 443,661 common shares and 4,110 preferred shares and SPEARHEAD INSURANCE SOLUIONS IDF, LLC - SERIES ADAR1 for 16,761 common shares and 387 preferred shares. The closing is expected to take place on or about June 28, 2024, subject to the satisfaction of customary closing conditions.